Abstract:Background: Recent studies have reported that an elevated intracellular glutathione (GSH) level is associated with resistance of non-small cell lung cancer (NSCLC) cell lines to cisplatin (CDDP). It is well-known that GSH is widely used in the clinic as a hepatoprotective agent. However, whether exogenous GSH can affect the sensitivity of NSCLC cells to CDDP remains unclear. The aim of this study is to evaluate the role of exogenous GSH in the resistance of A549 cells to CDDP. Methods: The effect of GSH and CDDP on the proliferation of A549 cells was analyzed by MTT assay. Subsequent experiments were conducted in A549 cells divided into four groups: control group (untreated cells), GSH group (treated with 120 mu g/ml GSH for 48 N. CDDP group (treated with 10 mu G/ml CDDP for 48 h) and CDDP+GSH group (treated with 10 mu g/ml CDDP+120 mu g/ml GSH for 48 M. Apoptosis was detected by flow cytometry. Light microscopy, fluorescence microscopy and electron microscopy were performed to study morphologic and ultrastructural differences among the four groups of cells. Intracellular GSH level and gamma-GCS expression were determined by immunohistochemistry (IHC). Cellular platinum uptake was assessed by inductively coupled plasma mass spectrometry (ICP-MS). Quantitative RT-PCR analysis was performed to measure the expression of caspase3, caspase9, bax, bc1-2 and MDR-1. Western blot analysis was conducted to examine the protein levels of GST-n, MRP-1 and P-gp. Results: Growth inhibition and apoptosis were reduced in A549 cells in the CDDP+GSH group compared to those in the CDDP group 48 h post-treatment. Alterations in cellular morphology and ultrastructure, as well as typical characteristics of apoptosis, were observed. Intracellular GSH and gamma-GCS levels were elevated by exogenous administration of GSH; in contrast, cellular platinum concentration fell rapidly. Relative to the CDDP group, the CDDP+GSH group exhibited 47.92%, 47.82% and 63.75% downregulation in caspase3, caspase9 and bax mRNA expression, respectively, and a 2.17-fold increase in bc1-2 mRNA level. In addition, there were 1.58-fold and 2.67-fold increases in the level of GST-n and MRP-1, respectively; however, the changes in MDR-1 and P-gp levels were not statistically significant. Conclusions: Our data demonstrated that exogenous GSH used as hepatinica in the clinic could induce resistance of A549 cells to CDDP by inhibiting apoptosis, elevating cellular GSH levels, inactivating the mitochondria-mediated signaling pathway, and increasingthe expression of GST-n, y-GCS and MRP1 to increase CDDP efflux.

Effects of Collagen Ⅳ on Chemotherapy-Induced Apoptosis of Cisplatin-Resistant Human Lung Adenocarcinoma Cells

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

COL3A1 Overexpression Associates with Poor Prognosis and Cisplatin Resistance in Lung Cancer

Role and mechanism of COL3A1 in regulating the growth, metastasis, and drug sensitivity in cisplatin-resistant non-small cell lung cancer cells

Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.

Effects of Polyphyllin I on Growth Inhibition of Human Non-Small Lung Cancer Cells and in Xenograft

The role of CTHRC1 in cisplatin-resistance of ovarian cancer cells and related mechanisms

Inhibitor of DNA Binding 3 Reverses Cisplatin Resistance in Human Lung Adenocarcinoma Cells by Regulating the PI3K/Akt Pathway.

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules

Exogenous Glutathione Contributes to Cisplatin Resistance in Lung Cancer A549 Cells.

5‐Nitro‐2‐(3‐phenylpropylamino) Benzoic Acid Induced Drug Resistance to Cisplatin in Human Erythroleukemia Cell Lines

Effects of rhTIMP-3 combined with DDP on growth inhibition and apoptosis of lung cancer cell A549

Effects Of Okadaic Acid Combined With Cisplatin On The Proliferation And Apoptosis Of Human Lung Adenocarcinoma A549 Cells

Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells

Nuclear Complement C3b Promotes Paclitaxel Resistance by Assembling the SIN3A/HDAC1/2 Complex in Non-Small Cell Lung Cancer

Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy.

Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells

Polyphyllin II (PPII) Enhances the Sensitivity of Multidrug-resistant A549/DDP Cells to Cisplatin by Modulating Mitochondrial Energy Metabolism.

Ginsenoside Rb3 Alleviates the Toxic Effect of Cisplatin on the Kidney During Its Treatment to Oral Cancer Via TGF-β-Mediated Mitochondrial Apoptosis.

Ailanthone Increases Cisplatin-induced Apoptosis and Autophagy in Cisplatin Resistance Non-small Cell Lung Cancer Cells through the PI3K/AKT/mTOR Pathway